Benefit of modified plasmapheresis in the management of myasthenia gravis: a case report.
Myasthenia gravis is an autoimmune disease condition caused by the generation of antibodies against the acetylcholine receptor sites at the neuromuscular junction. The treatment modalities include anticholinesterase drugs, corticosteroids, immunotherapy, thymectomy and plasmapheresis. However, because of the poor financial state of our patients and the dearth of appropriate equipment in our centres modifications are made to standard treatment modalities including plasmapharesis. We report a case of myasthenia gravis who was on various occasions on neostigmine, pyridostigmine and prednisolone. After about 18 months of treatment, he developed myasthenic crises on two occasions. He was admitted in the ICU for respiratory support where he also had modified plasmapheresis. The patient had remarkable improvement following the modified plasmapheresis with reversal of symptoms of the myasthenic crises. In the absence of facilities for standard plasmapheresis in this environment, the use of modified plasmapheresis is hereby recommended.